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Introduction: COPD has complex etiologies involving both genetic and environmental 
determinants. Among genetic determinants, the most recognized is a severe PiZZ (Glu342Lys) 
inherited alpha1-antitrypsin deficiency (AATD). Nonetheless, AATD patients present a 
heterogeneous clinical evolution, which has not been completely explained by sociodemographic 
or clinical factors. Here we performed the gene expression profiling of blood cells collected 
from mild and severe COPD patients with PiZZ AATD. Our aim was to identify differences in 
messenger RNA (mRNA) and microRNA (miRNA) expressions that may be associated with 
disease severity.
Materials and methods: Peripheral blood mononuclear cells from 12 COPD patients with 
PiZZ AATD (6 with severe disease and 6 with mild disease) were used in this pilot, high-
throughput microarray study. We compared the cellular expression levels of RNA and miRNA of 
the 2 groups, and performed functional and enrichment analyses using the Kyoto Encyclopedia 
of Genes and Genomes (KEGG) and Gene-ontology (GO) terms. We also integrated the miRNA 
and the differentially expressed putative target mRNA. For data analyses, we used the R statisti-
cal language R Studio (version 3.2.5).
Results: The severe and mild COPD–AATD groups were similar in terms of age, gender, exac-
erbations, comorbidities, and use of augmentation therapy. In severe COPD–AATD patients, 
we found 205 differentially expressed genes (DEGs) (114 upregulated and 91 downregulated) 
and 28 miRNA (20 upregulated and 8 downregulated) compared to patients with mild COPD–
AATD disease. Of these, hsa-miR-335-5p was downregulated and 12 target genes were involved 
in cytokine signaling, MAPK/mk2, JNK signaling cascades, and angiogenesis were much more 
highly expressed in severe compared with mild patients.
Conclusions: Despite the small sample size, we identified downregulated miRNA (hsa-miR-
335) and the activation of pathways related to inflammation and angiogenesis on comparing 
patients with severe vs mild COPD–AATD. Nonetheless, our findings warrant further valida-
tion in large studies.
Keywords: alpha1-antitrypsin deficiency, COPD, gene expression, miRNAs, integrative 
analysis
Introduction
COPD is the third leading cause of death worldwide. It is a complex disease influenced 
by both genetic and environmental determinants, the most important of which is 
cigarette smoking. However, only 10%–20% of smokers develop clinically significant 
disease, and there is a significant variability across the smokers with similar cigarette 
exposure. Some of these heterogeneities may be the result of genetic variations.1
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A known genetic risk factor for COPD is severe 
alpha1-antitrypsin deficiency (AATD). SERPINA1 is the 
gene responsible for the synthesis of the AAT protein, which 
is a serine protease inhibitor (serpin) and an acute-phase 
glycoprotein.2 Normal serum AAT levels are the result of 
2 copies of the common M allele of the SERPINA1 gene. 
The M allele of AAT is present in .90% of the population, 
and is called Pi*M. Over 100 SERPINA1 mutations have 
been identified to date, but only some are implicated in 
disease pathogenesis. The most frequent deficient alleles are 
S (Glu264Val) and Z (Glu342Lys), which are called Pi*S 
and Pi*Z, respectively. In particular, carriers of 2 Z alleles 
(PiZZ) have strongly reduced circulating levels of AAT 
(up to 10%–20% of normal, which is 1.3–2 g/L). Because 
of Z AAT misfolding and intracellular accumulation, the 
Z allele is the major contributor to pulmonary emphysema 
and liver disease in people of European ancestry.3–4
The evolution of emphysema in clinical terms and life 
expectancy are directly related to the accelerated loss of 
forced expiratory volume in 1 s (FEV
1
). Previous studies 
identified tobacco consumption and exacerbations as the main 
factors related to FEV
1
 decline.5 Lung function decline is 
faster in AATD compared with non-AATD COPD patients, 
although this is not homogeneous in all individuals.6–8
Recent genome-wide association studies (GWAS) and 
meta-analyses of GWAS have begun to shed light on biologi-
cal pathways that contribute to the development of COPD.9–11 
The analysis of the miRNA expression is increasingly used in 
clinical research. miRNAs belong to the family of small non-
coding RNAs (~21–25 nucleotides long), but they are involved 
in mRNA regulation.12 miRNAs modulate gene expression by 
either destabilizing transcripts or inhibiting protein transla-
tion. In fact, miRNAs may target up to one-third of the tran-
scriptome. Therefore, miRNA expression patterns in cells and 
tissues are considered to be biomarkers for both the diagnosis 
and prognosis of different diseases, including COPD.13–16 
mRNA and miRNA signatures can assist clinicians in prog-
nosis assessment and therapeutic approaches.12–18 However, 
the heterogeneity in study designs makes comparisons across 
studies difficult. Therefore, this field is naturally progressing 
toward the integration of miRNA with gene expression.19
In this context, some SERPINA1 gene expression studies 
have been performed.6 We propose that gene expression profil-
ing may provide new insights into the molecular mechanisms 
of AATD-related COPD and eventually lead to the identifica-
tion of novel therapeutic targets.20–21 Here, we explored the use 
of gene expression patterns in peripheral blood mononuclear 
cells (PBMCs) collected from PiZZ cases with severe and mild 
COPD. We aimed to identify differentially expressed putative 
mRNA and miRNAs in PBMCs isolated from patients with 
different severities of lung disease.
Materials and methods
Design and study sample
This study was a pilot high-throughput microarray experi-
ment. On the basis of the presence of poor lung function at 
diagnosis (FEV
1
,45% predicted), we included 6 patients 
considered to have rapid progression of emphysema (severe 
disease group). This severe group was compared with a 
group of 6 subjects matched for age and gender but with 
significantly better lung function at diagnosis (FEV
1
.65% 
predicted). We considered these patients to have slow dis-
ease progression (mild disease group). All the patients were 
recruited from the outpatient clinic of the respiratory depart-
ment of the Vall d’Hebron University Hospital (Barcelona, 
Spain) and all had undergone genotyping by sequenc-
ing of all coding exons of SERPINA1. Signed informed 
consent was obtained from all subjects for participation 
in the study, and the study was approved (project ID: PR 
(AG)157/2016) by the Ethics Committee of the Research 
Institute of Hospital Vall d´Hebron (Barcelona, Spain).
All the patients presented clinical stability, defined as no 
respiratory ambulatory exacerbations or hospital admission in 
the previous 2 months. They were followed and treated accord-
ing to guidelines.22 Some patients were receiving intravenous 
therapy with plasma purified AAT (Prolastin or Trypsone; Gri-
fols, Barcelona, Spain) at a dose of 120 mg/kg for 15 days.
As previous studies have shown that AAT therapy may 
indirectly reduce the expression of Z-AAT,23 blood samples 
were taken immediately before the next infusion in patients 
receiving augmentation therapy.
Variables and data collection
Sociodemographic, clinical (phenotype, age at diagnosis, 
current age, age at onset of symptoms, tobacco consumption, 
comorbidities, exacerbations, and treatments), and lung function 
data at the time of AATD diagnosis were collected from medical 
records. Lung function tests were performed according to stan-
dardized recommendations and international guidelines.24–25
Blood processing and RNA isolation
Blood processing and RNA isolation was carried out at 
the Biobank at the Vall d’Hebron Research Institute (VHIR), 
Barcelona, Spain. PBMCs were isolated from AATD patients 
using Ficoll gradient centrifugation. Total RNA and miRNA 
were isolated from PBMCs using the QuickGene RNA tissue 
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SII (RT-S2) kit and QuickGene 810 FUJIFILM device. 
miRNA was also isolated from PBMCs using QIAzol Lysis 
Reagent (Qiagen, Hilden, Germany) and the miRNeasy Mini 
Handnook Kit (Qiagen). RNA and miRNA concentrations 
were determined with a NanoDrop ND2000 spectrophotom-
eter and quality was checked using a Bioanalyzer (Agilent 
Technologies, Hilden, Germany) with Eukariotic NanoChip 
before microarray analysis.
rna and mirna microarray 
hybridization
The RNA and miRNA microarrays were performed at the High 
Technology Unit (UAT) of the VHIR. In this experiment, the 
Affymetrix GeneTitan microarray platform and the Genechip 
Human Gene Array Plate 2.1 were used for RNA hybridiza-
tion. This array analyzes gene expression patterns on a whole-
genome scale on a single array with probes covering many 
exons on the target genomes, thereby providing expression 
summarization at the exon or gene level. The starting material 
was 200 ng of total RNA of each sample. Briefly, sense single-
stranded DNA (ssDNA) suitable for labeling was generated 
from total RNA with the GeneChip WT Plus Reagent Kit from 
Affymetrix (High Wycomb, UK) according to the manufac-
turer’s instructions. Sense ssDNA was fragmented, labeled, 
and hybridized to the arrays with the GeneChip WT Terminal 
Labeling and Hybridization Kit from the same manufacturer.
The Affymetrix GeneTitan microarray platform and the 
Genechip miRNA array plate 4.1 were used for miRNA 
hybridization. The starting material was 400 ng of total RNA 
of each sample. miRNA in the sample was labeled using 
the Flash Tag Biotin HSR RNA Labeling Kit following the 
manufacturer’s instructions.
We used a unique miRNA and 2 mRNA microarray 
batches in our experiments. Distribution of severe and mild 
patient samples within the batches was similar.
statistical analysis for comparison of 
patient characteristics
The results of the statistical analyses are expressed as mean 
(SD) for quantitative variables and as valid percentage for 
groups using the nonparametric Mann–Whitney U or chi-
square tests (Fisher’s exact test when the expected frequen-
cies were ,5).
Data preprocessing and analysis of 
differentially expressed genes
First, a raw data quality control was performed before 
normalization in order to analyze sample quality, hybridization 
quality, signal comparability and biases, array correlation, 
and probe sets’ homogeneity.
Background correction and quantile normalization were 
performed for the raw array data using the oligo package 
(http://www.bioconductor.org/)26 and robust multi-array 
average (RMA package for R).27 For each sample, the expres-
sion values of all probes for a given gene were reduced 
to a single value by taking the average expression value. 
Principal component analysis (PCA) was performed and a 
hierarchical clustering plot was made after normalization. 
Batch effects were analyzed using surrogate variable analysis 
(SVA package)28 and Combining Batches of Gene Expression 
Microarray Data (ComBat) functions.29
Before differentially expressed genes (DEGs) analysis, 
present probes without the corresponding gene symbols 
and expression intensities below the 3rd quartile value were 
removed for further statistical analysis. The Limma (Linear 
Models for Microarray Data) package30 was used to perform 
statistical testing of differential mRNA and miRNA expres-
sion between the 2 study groups. Differentially expressed 
mRNAs and miRNAs were defined as having a P-value 
of ,0.05 with at least ±1.5-fold change (FC) (logFC ±0.58) 
between the groups. P-values adjusted for the false discovery 
rate (FDR) were also calculated.
Degs annotation and pathway-
enrichment analyses
DEGs were annotated identifying the beginning and the 
end of the chromosome as well as the gene symbol with 
the BioMart R package (http://www.biomart.org) and 
the Affymetrix annotation files.
Kyoto Encyclopedia of Genes and Genomes (KEGG) 
and Gene-ontology (GO) terms31 were enriched for DEGs 
using the Gene Expression Omnibus (https://www.ncbi.nlm.
nih.gov/geo/) database. The major GO terms associated with 
biological processes was manually summarized based on 
gene-term enrichment provided for each functional group at a 
Fisher’s exact P-value of 0.05. The same statistical approach 
was used for KEGG analysis.
miRNA and mRNA data integration
Integration of miRNA DEGs and their target mRNA DEGs 
was performed using the multiMiR R package with the 
web server at http://multimir.ucdenver.edu. This is a com-
prehensive collection of predicted and validated miRNA–
target interactions and their associations with diseases and 
drugs.32 All the analyses were performed using the R Studio 
(version 3.2.5).





Quantitative reverse transcription 
polymerase chain reaction validation
For all the samples, an independent analysis of EGR3 and 
EREG expression was performed by the quantitative reverse 
transcription polymerase chain reaction (qRT-PCR) method. 
The levels of expression of selected genes were analyzed using 
the TaqMan Gene Expression Assay (Applied Biosystems, Life 
Technologies, Madrid, Spain). The expression of the reference 
gene, hypoxanthine phosphoribosyl transferase (Life Technolo-
gies, #Hs02800695_m1), was used for normalization. Relative 
gene expression was calculated according to the ∆ cycle thresh-
old method using StepOne software. Statistical significance was 
defined as P,0.05 as measured using the Student’s t-test.
Results
Blood PBMCs were isolated from 12 PiZZ patients: 6 with 
severe emphysema with a mean FEV
1
(%) of 44% (SD =6.7%) 
and 6 with mild disease, with FEV
1
(%) of 93% (SD =29%). 
Both study groups presented similar characteristics in terms 
of age, gender, exacerbations, comorbidities, and time from 
the last infusion. Severe patients were diagnosed at a younger 
age than mild patients (42.7 years [SD =6.4] vs 51.2 [SD =4.0], 
P=0.041) and all received inhaled corticosteroids (Table 1). 
Two patients from the severe group were current smokers 
and, therefore, did not receive replacement therapy. None of 
the patients in either group received systemic corticosteroids. 
The time from blood collection and processing in the laboratory 
was compared between groups without statistical differences.
mrna analysis
Initially, the mRNA expression of 53,617 probe sets corre-
sponding to 12 samples were included. Data were normalized 
and after filtering, a total of 10,143 probes were used for the 
following analysis. We found no batch effects according to 
the time of blood processing, study group, or gender (data 
not shown).
Normalized PCA results showed that the first axis explained 
16% of the variance. Two samples corresponding to current 
smokers from the severe group presented a different gene 
expression profile according to the second axis that explained 
10.5% of the variability. To avoid a potential gene expression 
bias, these 2 samples were removed from the following analyses. 
Finally, 10 AATD samples (4 from the severe and 6 from the 
mild disease groups) were included in the DEGs analysis.
A total of 205 DEGs differed between severe and mild 
patients, of which 114 genes were upregulated and 91 down-
regulated in severe patients using non-adjusted P-value 








Age (years) at the time of the 
study
61.7 (7.7) 61.0 (10.5) 0.937
Age (years) at diagnosis 51.2 (4) 42.7 (6.4) 0.041
gender 0.999
Male (%) 4 (66.7) 4 (66.7)
Female (%) 2 (33.3) 2 (33.3)
Smoking history 0.135
Never (%) 2 (33.3) 0
Current (%) 0 2 (33.3)
Former (%) 4 (66.7) 4 (66.7)
FeV1% 93 (29) 44 (6.7) 0.002
AAT blood levels (mg/dL) 22 (5) 27 (5.1) 0.265
Other comorbidities
Bronchiectasis 1 (16.7) 1 (16.7) 0.098
Cardiovascular diseases 1 (16.7) 2 (33.3) 0.125
Inhaled respiratory 
treatments (%)
4 (66.7) 6 (100) 0.225
Beta2 agonists (%) 4 (66.7) 6 (100) 0.065
Inhaled corticosteroids (%) 0 6 (100) 0.025
Replacement therapy (RT) (%) 2 (33.3) 4 (66.7) 0.248
Time from last rT 
infusion (days)
15 15 0.999
Time from blood collection 
to sample process (minutes)
74.2 (49.6) 68.3 (23.2) 0.589
Notes: Data are expressed as mean (SD) or n (valid percentage). Bold values 
indicate p,0.05.
Abbreviations: aaT, alpha1-antitrypsin; FeV1, forced expiratory volume in 1 s.
Figure 1 Differentially expressed genes in severe (blue line) vs mild (green line) 
patients.
Notes: Two-dimensional hierarchical clustering of the 10 samples according to the 
expression of 205 genes differentially expressed (by row) comparing severe (n=4) vs 
mild (n=6) patients (by column), with a P-value of ,0.05 and fold changes (FC) .±1.5 
(logFC .±0.58) using the Limma (Linear Models for Microarray Data) method. The 
functional classification of genes (color-coded) is shown. Red represents a high level 
of gene expression while blue represents a low level of expression.
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FDR P-values were calculated, but no differences were 
found in gene expression between the 2 groups. There-
fore, for all the following analyses, we used non-adjusted 
P-values.
The top dysregulated mRNAs are shown in Table 2. 
Upregulated genes with highest difference between the 
2 groups (logFC .1) included HLA-DRB5, OLFM4, 
HBEGF, LFT, MMP8, CXCL8, SOCS3, CAMP, G0S2, 
CCL3L3, EREG, EGR3, NR4A2, JUP, and IL1B genes.
These genes are involved in systemic and local inflam-
mation, immunity, proliferation, differentiation, apoptosis, 
and oncogenesis. We found that these groups of genes are 
enriched in different pathways such as the mitogen-activated 
protein kinases (MAPK) cascade pathway, the Jun amino-
terminal kinases (JNK) cascade, the Janus kinase/signal 
transducers and activators of transcription (JAK/STAT) 
signaling pathway, the NOD-like receptor pathway, and the 
Toll-like receptor signaling pathway using GO and KEGG 
terms (Tables 3 and 4).
mirna Degs analysis
The miRNA data were analyzed using the same pipeline 
as in mRNA data analysis. Initially, a quality control of 
6,658 miRNA probes was performed and after filtering, 
1,165 miRNA were included in the Limma analysis. A total 
of 28 miRNAs were found to be differently expressed in 
PBMCs from severe compared to mild AATD emphysema 
patients, with 20 miRNAs being upregulated and 8 being 
downregulated in severe patients (Table 5).
All the dysregulated miRNAs are shown in Table 5. 
Upregulated miRNA included hsa-miR-146b-3p, hsa-miR-
146b-5p, hsa-miR-193b-3p, and hsa-miR-365a-5p, whereas 
downregulated miRNAs included hsa-miR-486-3p and hsa-
miR-335-5p. The latter 2 have previously been reported to 
be related to respiratory diseases.
mirna and mrna interactions
As shown in Table 6, we identified 3 putative miRNA inter-
acting targets between differentially expressed miRNAs and 
DEGs. Our analysis showed significant downregulation of 
hsa-miR-335-5p in severe patients, which was significantly 
linked to 12 upregulated transcripts, enriched in the cytokine-
mediated signaling pathway, the MAPK/mk2 signaling 
cascade, the JNK cascade, and angiogenesis (Table 6).
qrT-PCr validation of Degs
We randomly selected EREG and EGR3 genes to be verified 
by qRT-PCR. We have chosen these 2 genes with lower FCs, 
hoping to reproduce our findings by using an independent 
method. In accordance with microarray data, the expression 
of both genes was significantly higher in PBMCs from severe 
than from mild AATD emphysema patients (Figure 2).
Discussion
One of the important issues in developing biomarkers for 
clinical purposes is the selection of appropriate cells or 
tissues from which candidates can be identified. Because 
of the systemic nature of COPD/emphysema33 and because 
of unique properties of AAT protein,34 we hypothesized 
that genome-wide expression profiling of peripheral blood 
cells may be used to identify signatures of AATD-related 
emphysema phenotypes. PBMCs are attractive candidates 
because they are easy to obtain and simple to prepare. There-
fore, here we performed the gene expression profiling of 
PBMCs collected from severe and mild emphysema patients 
with PiZZ AATD. Our objective was to identify putative 
differences in mRNA and miRNAs expression that might 
be associated with disease severity. The microarray analy-
sis of PBMCs isolated from 10 emphysema patients with 
Table 2 Top dysregulated mRNA comparisons in peripheral 
































Note: Table 2 shows different miRNAs using a P-value ,0.05 and logFC .±1.
Abbreviations: AATD, alpha1-antitrypsin deficiency; IL-8, interleukin-8; logFC, 
fold change logarithm; MMP, matrix metalloproteases protease; mRNA, mes-
senger RNA.





PiZZ AATD revealed that cells from patients with severe 
disease presented 205 differentially expressed mRNAs 
(114 upregulated and 91 downregulated) and 28 miRNAs 
(20 upregulated and 8 downregulated) compared to those 
from patients with mild disease. Moreover, we found an 
interaction between downregulated hsa-miR-335-5p and 
12 upregulated target gene mRNAs. These latter genes are 
related to the cytokine-mediated signaling pathway, the 
MAPK/mk2 signaling cascade, the JNK cascade, and angio-
genesis. It is important to remark that all our patients were 
clinically stable and took their usual respiratory treatment 
at inclusion in the study.
In the cells of severe patients, we found a higher expression 
of the EREG, EGR3, and TRIB1 genes, which are involved in 
inflammatory response-related signal transduction pathways 
including MAPK.35 EGR3 is a zinc finger transcription factor, 
an immediate-early response protein activated by cellular 
stressors.36 As a major transcription factor, EGR3 alters the 
expression of several target genes, including repair enzyme 
systems, angiogenic factors, cytokines (interleukin-8 [IL-8] 
Table 3 Gene ontology functional enrichment analysis of the DEGs between peripheral blood mononuclear cells isolated from severe 
vs mild aaTD emphysema patients
GO ID Term Odds ratio P-value DEGs
Upregulated
0043408 Regulation of MAPK cascade 4.8 9.03e-07 ATF3, CCR1, HBEGF, DUSP1, EREG, ID1, IL1B, OSM, 
PARK2, TPD52L1, VEGFA, WNT7A, ARHGEF5, TRIB1, 
DACT1, AVPI1, CARD9, DUSP16, CCL3L3, CD24
0001525 Angiogenesis 4.68 4.41e-05 ADM, ANPEP, EGR3, EREG, NR4A1, ID1, IL1B, CXCL8, 
MFGE8, PTGS2, VEGFA, WNT7A, PLXDC1
0001817 Regulation of cytokine production 4.17 7.3e-05 CAMP, CD14, CLC, EREG, HLA-DRB5, IL1B, LTF, PTGS2, 
nr4a3, sOCs1, CleC5a, CarD9, aTg9a, CD24
0007254 JnK cascade 6.17 9.2e-05 IL1B, PARK2, TPD52L1, WNT7A, ARHGEF5, TRIB1, 
DaCT1, CarD9
001937 Cyclooxygenase pathway 39.6 0.00012 PTgDs, PTgs2, hPgDs
0019221 Cytokine-mediated signaling pathway 3.55 0.00019 CCR1, EGR1, EREG, CXCL2, HLA-DRB5, IL1B, CXCL8, 
OSM, PARK2, SOCS1, SOCS3, CCL3L3, CD24
0007249 I-kappaB kinase/NFκB signaling 4.51 0.00068 CD14, IL1B, LTF, PARK2, PTGS2, OLFM4, PLK2, CARD9
Downregulated
0043949 Regulation of cAMP-mediated signaling 25.7 0.00345 CXCL10, PTGIR
0035490 Regulation of leukotriene production 
involved in inflammatory response
Inf 0.00382 serPIne1
0055118 Negative regulation of cardiac muscle 
contraction
265 0.00762 PDesa
0007599 hemostasis 3.75 0.0034 A2M, SERPINE1, PTGIR, TFPI, PDE5A, P2RY12, HIST2H3D
0006950 response to stress 2.44 0.000726 A2M, HLA-DQB1, HLA-DRB1, IGFBP4, CXCL10, OAS3, 
SERPINE1, PDK4, PTGIR, XCL2, TFPI, HIST1H2BG, 
HIST1H2BF, HIST2H2BE, PDE5A, MTSS1, DCLRE1A, 
PDCD6, KLRG1, CRTAM, P2RY12, TNIP3, ZKSCAN3, 
DUSP19, HIST2H3D, GTF2H2C_2
Abbreviations: AATD, alpha1-antitrypsin deficiency; cAMP, cyclic adenosine monophosphate; DEGs, differentially expressed genes; GO, gene ontology; JNK, jun amino-
terminal kinases; MAPK, mitogen-activated protein kinases; NFκB, nuclear factor kappa B.
Table 4 Kegg functional enrichment analysis of the Degs between peripheral blood mononuclear cells isolated from severe vs mild 
aaTD emphysema patients
KEGG ID Term Odds ratio P-value DEGs
04640 Hematopoietic cell lineage 5.7 0.0014 ANPEP, CD14, HLA-DRB1, HLA-DRB5, IL1B, CD24
00590 arachidonic acid metabolism 5.9 0.00654 PTgDs, PTgs2, hPgDs, Pla2g2C
04621 nOD-like receptor pathway 5.9 0.00625 CXCL2, IL1B, CXCL8, CARD9
04060 Cytokine–cytokine receptor interaction 2.89 0.00786 CCR1, CXCL2, IL1B, CXCL8, OSM, XCL2, VEGFA, CCL3L3
05310 asthma 8.29 0.00769 HLA-DQB1, HLA-DRB1, HLA-DRB5
04062 Chemokine signaling pathway 2.69 0.036 CCR1, CXCL2, CXCL8, CXCL10, XCL2, CCL3L3
04620 Toll-like receptor signaling pathway 3.14 0.046 CD14, IL1B, CXCL8, CXCL10
Abbreviations: AATD, alpha1-antitrypsin deficiency; DEGs, differentially expressed genes; KEGG, Kyoto Encyclopedia of Genes and Genomes; NOD, nucleotide-binding 
oligomerization domain.
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and tumor necrosis factor-alpha [TNFα]), apoptotic factors 
(Fas), cell cycle factors (p21 and p53), metabolic factors, 
and matrix metalloproteases proteases (MMPs). In parallel to 
EGR3, we also found a higher expression of cytokines (IL1B, 
CCL3L3, and CXCL8). Hence, there may be a direct link 
between EGR3 and cytokine expression, which has already 
been validated as a target gene in respiratory inflammation 
and different cancers.37
The activation of members of the MAPK family triggers 
the activation of transcription factors such as the nuclear 
factor kappa B (NFκB) subunit 1.38 Activation of NFκB 
eventually results in the expression of a battery of genes 
that regulate inflammatory, apoptotic, and proliferative 
responses associated with the pathogenesis of emphysema.39 
Previous studies have shown the activation of NFκB in the 
bronchial biopsies and inflammatory cells of non-AATD 
COPD patients.40 Gene expression profiling studies have 
revealed that inflammatory cytokine- and chemokine-related 
genes (ie, fractalkine/CX3CL1) are significantly increased 
in stable non-AATD-COPD patients, becoming more pro-
nounced during COPD exacerbations.21,41
Transcripts involved in the JNK cascade pathway were 
also upregulated in severe compared to mild COPD patients. 
Recent data by Pastore et al42 revealed that JNK and c-JUN 
play a role in SERPINA1 gene transcriptional upregulation in 
AATD-related liver disease. To date, however, there are no 
studies investigating the impact of JNK on the pathogenesis 
of AATD.
Changes in miRNA expression are associated with the 
development and progression of cancer, and cardiovascu-
lar and inflammatory pulmonary diseases.13,43 We found 
8 miRNAs to be downregulated in PBMCs from severe 
patients, including hsa-miR-486-3p and hsa-miR-335-5p, 
which have previously been reported to be related to respira-
tory diseases. Downregulation of hsa-miR-335-5p involves 
the activation of pathways related to inflammation and 
angiogenesis. Therefore, our analysis suggests a potential 
novel link between decreased miR-335-5p expression and 
the severity of AATD-related emphysema. The integra-
tive analysis revealed that miR-335-5p interacts with other 
miRNAs previously described in emphysema. For example, 
high expression of hsa-miR 146-5p in cells from severe 
Table 5 Dysregulated miRNA in peripheral blood mononuclear 
cells from severe compared with mild aaTD emphysema 
patients































Note: Table 5 shows different miRNAs using P-value ,0.05 and logFC .±1.
Abbreviations: AATD, alpha1-antitrypsin deficiency; logFC, fold change logarithm; 
mirna, microrna.
Table 6 miRNA–target interactions between differentially 























hsa-mir-874-3p hIsT1h4h 0.001 -1.2
hsa-mir-193b-3p hIsT2h3D 0.002 -0.6
Notes: Integration of validated and predicted interactions between miRNAs and 
their target genes using multiMiR R package. Comparisons were performed using a 
P-value ,0.05 and FC .±1.5 (logFC .±0.58).
Abbreviations: AATD, alpha1-antitrypsin deficiency; logFC, fold change logarithm; 
mirna, microrna.





patients supports the findings by Ezzie et al,18 who stated that 
miR-146a expression is higher in lung tissue from patients 
with COPD than in non-COPD smokers. In contrast, Sato 
et al44 reported reduced expression of miR-146a in cultured 
fibroblasts from COPD subjects. miR-146a was down-
regulated in sputum of patients with COPD and smokers 
compared with never-smokers, and in smokers with COPD 
in comparison to smokers without COPD.45 Overall, recent 
studies support the hypothesis that miR-146a and miR-146b 
play a role in the regulation of inflammatory pulmonary 
disorders.46
The results of the present study provide additional support 
for the role of miRNAs in COPD and improve the understand-
ing of the molecular mechanisms underlying the expression 
of peripheral inflammatory cells in patients with severe and 
mild AATD-related emphysema.
Limitations
We found significant differences in the expression patterns 
of genes between severe and mild emphysema patients with 
PiZZ AATD. However, the results from this small pilot 
study must be complemented by the inclusion of a control 
group of patients with non-AATD–related COPD. A con-
trol group would help to clarify whether the activation of 
pathways related to inflammation, immune response, and 
angiogenesis are the cause or the effect of more progressed 
emphysema. Golpon et al35 found some degree of shared gene 
profiles between “usual” non-AATD–related emphysema 
Figure 2 Quantitative reverse transcription polymerase chain reaction.
Note: Validation of ereg (A) and EGR3 (B) expression compared with housekeeping gene hypoxanthine phosphoribosyl transferase (HPRT).
Abbreviation: mRNA, messenger RNA.
and AATD-related emphysema. These authors observed 
statistically significant differences in the modulation of 
genes associated with protein and energy metabolism and 
immune function, which allow differentiation between these 
2 emphysema types at the lung tissue level. We are aware that 
differences in the genetic signatures of PBMCs isolated from 
severe vs mild PiZZ AATD patients need to be validated in 
a larger study population.
In our analysis, 12 samples were initially included, but 
2 current smokers were excluded from the patient group with 
severe AATD emphysema. According to the quality control 
analysis, the gene expression profile of these individuals 
was markedly different compared with the other samples. 
Cigarette smoke is a complex mixture of .4,000 chemical 
compounds that can induce a variety of biological responses, 
including oxidative stress, apoptosis, and inflammation, 
among others.47 In general, most studies report a global 
downregulation and upregulation of miRNA and mRNA 
abundance in response to cigarette smoking.18,48 We plan 
to perform a separate study to analyze the gene expression 
profiles in PBMCs isolated from smokers with severe and 
mild COPD.
The cellular gene expression pattern may be influenced 
by multiple factors, such as patient age, gender, genetic 
background, and treatment. Replacement therapy could have 
influenced gene expression. Some studies have suggested that 
replacement therapy may reduce airway inflammation.49–51 
However, Olfert et al52 found that replacement therapy 
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reduces the concentration of TNF-alpha, but has no effect on 
IL-6, IL1B, or C-reactive protein. In our study, 4 severe and 
2 mild emphysema AATD patients received augmentation 
therapy every 15 days. To minimize the potential effect of 
replacement therapy, blood samples were taken just before 
the patients received the next infusion. However, it would be 
important to include PBMCs from patients who have never 
received augmentation therapy.
Conclusion
The findings of this analysis provide novel information 
about the different gene profile of PBMCs isolated from 
patients with severe and mild emphysema with PiZZ AATD. 
We specifically identified downregulated miRNA (hsa-miR-
335) in severe AATD patients. The hsa-miR-335-5p regulates 
important transcription factors involved in the activation of 
pathways directly related to inflammation and angiogenesis 
and could play an important role in the pathogenesis of this 
rare condition. Nevertheless, further analyses are needed to 
validate these results.
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